Malin eyes more investments and returning cash in 2022
Litigation-related costs came to €400,000 last year as founders sue for direct stake
Irish-founded software company Qualio raises $50m in funding
Company is behind a quality management software platform for the life sciences sector
Time for Malin to decide what it wants to be when it grows up
Market Beat: Life sciences company is finally delivering, six years after IPO
Irish-founded software company Qualio raises $11m
Company has developed a quality management platform for life sciences sector
Malin-backed company announces initial IPO price
Poseida Therapeutics is expected to begin trading on the Nasdaq on Friday
Malin-backed Poseida raises $110m just days after filing for IPO
Dublin-listed life-sciences investment group did not participate in latest financing
Irish bank shares jump as European markets cheer economic data
Scandal-hit Wirecard rallied after three consecutive slumps
Malin sees clinical trials delays amid Covid-19 crisis
Germ-zapping robot firm backed by Malin sees spike in demand amid virus outbreak
Malin investee company Immunocore raises in excess of $130m
Irish life-sciences company invested $80m in Oxford-based company in July 2015
US hedge fund snaps up Woodfords’ Malin stake
Pentwater bought shares at 60% discount to Malin’s ‘intrinsic value’
Woodford sells remaining Malin stake
Troubled asset manager thought to have sold 1.6m shares earlier this week
Woodford effect lingers at Malin despite shares sell-off
Once-revered UK stock picker still linked to Irish life-sciences investment company
Malin chief sees demand for 23% Woodford stake
New CEO says company will have enough investor demand to absorb the holding if sold
Malin names Darragh Lyons CEO as investments value drops
Value of portfolio fell 5% in first half of the year
Malin-backed eczema drug company signals IPO
Biopharmaceutical company Kymab identified as one of Malin’s four ‘core assets’
Malin chairman Ian Curley signals departure plans
Business veteran has overseen review of investment group’s portfolio
Malin investee company Poseida Therapeutics files for potential US IPO
US clinical-stage biotechnology company is eyeing a listing on the Nasdaq Global Select Market
Malin pledges to return cash to shareholders
Four main assets on track to reach ‘important milestones’
Malin chief executive to step down after just one year in the role
Former Ardagh CEO Ian Curley to become executive chairman on an interim basis
Boardroom bloodbath averted, can Malin finally deliver on its promise?
Plus, good times return for top AIB clients
Malin portfolio value rises to €402m in first half of 2018
Company says it will focus on core assets, which account for more than 70% of portfolio
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices